Cumulus Neuroscience to Partner with The Digital Medicine Society

Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data, today announced a partnership with the Digital Health Measurement Collaborative Community (DATAcc) by the Digital Medicine Society (DiMe).

Cumulus will participate in the DATAcc by DiMe Building the Business Case for Digital Endpoints project, which will convene leaders from across the field to establish shared industry benchmarks for evaluating the return on investment (ROI) of digital endpoints in the development of drugs, medical devices, and other regulated interventions. Outputs of the project will include a value framework, industry benchmarking tools, ROI forecasting models, and a modular template to support innovators developing the business case for digital endpoints in the development, implementation, and scale of fit-for-purpose digital measures as endpoints in clinical trials.